- Beovu Webinar series: “The art of vision: Beovu® in the real world"
- Beovu Webinar by Dr Siedlecki (25/09/2020) – Full replay
- Beovu Webinar by Dr Siedlecki (25/09/2020) – Video fragments
BE2307074052
×
Ask the speakers
Gerelateerde inhoud
Wet AMD Visual acuity and outcomes with Beovu in clinical trials
At Week 48, brolucizumab demonstrated non-inferiority to aflibercept in mean BCVA change from baseline in HAWK (p<0.001). • Visual acuity gains achieved at Week 48 with a majority of patients on a q12w interval 1 • The vision gains were maintained at Week 96 2 • In both trials, ~30% of...Toon meer
BE2307074052
▼Beovu ® (brolucizumab) is indicated in adults for the treatment of neovascular (wet) AMD and visual impairment due to DME 1 Safety profile with Beovu in clinical trials Beovu exhibited an overall well-tolerated safety profile in wet AMD patients in HAWK & HARRIER and DME patients in KESTREL and KITE 1–5 Toon meer
BE2307074052